Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achillion Pharmaceuticals has commenced dosing in a Phase 1 trial to evaluate ACH-2928 as a treatment of chronic hepatitis C virus (HCV) infection.
Subscribe to our email newsletter
The double-blind, randomized and placebo-controlled trial will recruit around 48 healthy subjects and 20 HCV genotype 1 treatment naive patients in the US.
Achillion president and CEO Michael Kishbauch said over the next few quarters, they plan to achieve human proof-of-concept on ACH-2928 and to advance an additional NS5A inhibitor into clinical development.
"Furthermore, we intend to obtain additional clinical results from our protease inhibitor programs including 12-week EVR results from the Phase 2a trial with ACH-1625 and to establish clinical proof-of-concept on ACH-2684, our pan-genotypic agent being evaluated in Phase 1," Kishbauch said.